SPONSOR
National Heart, Lung, and Blood Institute (NHLBI)
Total Trials
12
Recruiting
12
Phases
EARLY_Phase 1, Phase 1
Conditions studied: Vascular DysfunctionGenetic MutationsGenetic PredispositionSickle CellPKLR VariantsAdenosine Triphosphate ActivitiesChronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Coronary DiseaseMortality in Sickle Cell
National Heart, Lung, and Blood Institute (NHLBI) is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including Vascular Dysfunction, Genetic Mutations, Genetic Predisposition, Sickle Cell.
The trial portfolio spans EARLY_Phase 1, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — National Heart, Lung, and Blood Institute (NHLBI)
How many clinical trials has National Heart, Lung, and Blood Institute (NHLBI) sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by National Heart, Lung, and Blood Institute (NHLBI), of which 12 are actively recruiting participants. These trials cover conditions including Vascular Dysfunction, Genetic Mutations, Genetic Predisposition. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does National Heart, Lung, and Blood Institute (NHLBI) research focus on?
National Heart, Lung, and Blood Institute (NHLBI) clinical trials span Vascular Dysfunction, Genetic Mutations, Genetic Predisposition, Sickle Cell, PKLR Variants, and additional conditions. The research pipeline includes EARLY_Phase 1, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a National Heart, Lung, and Blood Institute (NHLBI) clinical trial?
To participate in a National Heart, Lung, and Blood Institute (NHLBI) trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all National Heart, Lung, and Blood Institute (NHLBI) trials with current recruitment status updated daily.
Clinical Trials by National Heart, Lung, and Blood Institute (NHLBI)
NCT03538639
Recruiting
Vascular Disease Discovery Protocol
Vascular Dysfunction
NCT03685721
Recruiting
Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease
Sickle Cell
NCT07428707 EARLY_Phase 1
Recruiting
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
Chronic Lymphocytic Leukemia (CLL)
NCT01621594
Recruiting
Evaluating New Radiation Techniques for Cardiovascular Imaging
Coronary Disease
NCT05213572
Recruiting
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Mortality in Sickle Cell
NCT05724121
Recruiting
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Chronic Lymphocytic Leukemia (CLL)
NCT06552767
Recruiting
Thrombosis and Inflammation in Vessels Initiative (TIVI)
Cardiovascular Diseases
NCT06615986 EARLY_Phase 1
Recruiting
Human Milk Oligosaccharide-Based Synbiotic Supplement for Intestinal Microbiota Dysbiosis
Healthy Volunteers
NCT04014348
Recruiting
Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women
Cardiovascular (CV) Risk
NCT04216342 Phase 1
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
Cardiovascular Disease
NCT07516379
Recruiting
GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation
Lung Transplant
NCT00923507
Recruiting
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology